392 related articles for article (PubMed ID: 28582669)
1. QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.
Gomes MN; Braga RC; Grzelak EM; Neves BJ; Muratov E; Ma R; Klein LL; Cho S; Oliveira GR; Franzblau SG; Andrade CH
Eur J Med Chem; 2017 Sep; 137():126-138. PubMed ID: 28582669
[TBL] [Abstract][Full Text] [Related]
2. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.
Lilienkampf A; Pieroni M; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2010 Jan; 53(2):678-88. PubMed ID: 20000577
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
4. Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Pieroni M; Franzblau SG; Bishai WR; Kozikowski AP
Curr Top Med Chem; 2012; 12(7):729-34. PubMed ID: 22283815
[TBL] [Abstract][Full Text] [Related]
5. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
Martins F; Ventura C; Santos S; Viveiros M
Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
[TBL] [Abstract][Full Text] [Related]
7. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
8. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-Mycobacterium tuberculosis activity of imide-β-carboline and carbomethoxy-β-carboline derivatives.
Lopes-Ortiz MA; Panice MR; Borges de Melo E; Ataide Martins JP; Baldin VP; Agostinho Pires CT; Caleffi-Ferracioli KR; Dias Siqueira VL; Bertin de Lima Scodro R; Sarragiotto MH; Cardoso RF
Eur J Med Chem; 2020 Feb; 187():111935. PubMed ID: 31816556
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.
Wu Y; Cheung CY; Zhou Y; Wang Z; Tu Z; Cook GM; Lu X
Bioorg Med Chem; 2021 Nov; 49():116426. PubMed ID: 34624820
[TBL] [Abstract][Full Text] [Related]
14. Nontoxic Metal-Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis.
Yu M; Nagalingam G; Ellis S; Martinez E; Sintchenko V; Spain M; Rutledge PJ; Todd MH; Triccas JA
J Med Chem; 2016 Jun; 59(12):5917-21. PubMed ID: 27214150
[TBL] [Abstract][Full Text] [Related]
15. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
16. QSAR Studies, Synthesis and Antibacterial Assessment of New Inhibitors Against Multidrug-Resistant Mycobacterium tuberculosis.
Kovalishyn V; Brovarets V; Blagodatnyi V; Kopernyk I; Hodyna D; Chumachenko S; Shablykin O; Kozachenko O; Vovk M; Barus M; Bratenko M; Metelytsia L
Curr Drug Discov Technol; 2017; 14(1):25-38. PubMed ID: 27829331
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Design of Isonicotinic Acid Hydrazide Derivatives: Machine Learning Studies, Synthesis and Biological Evaluation of their Antituberculosis Activity.
Kovalishyn V; Hodyna D; Sinenko VO; Blagodatny V; Semenyuta I; Slivchuk SR; Brovarets V; Poda G; Metelytsia L
Curr Drug Discov Technol; 2020; 17(3):365-375. PubMed ID: 30973110
[TBL] [Abstract][Full Text] [Related]
18. Azide-alkyne cycloaddition en route to 4-aminoquinoline-ferrocenylchalcone conjugates: synthesis and anti-TB evaluation.
Singh A; Viljoen A; Kremer L; Kumar V
Future Med Chem; 2017 Oct; 9(15):1701-1708. PubMed ID: 28869400
[TBL] [Abstract][Full Text] [Related]
19. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
Rajkhowa S; Deka RC
Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
